Research Progress of Glioma Immunotherapy / 中山大学学报(医学科学版)

ABSTRACT

@#Gliomas are the most common primary malignant tumors in the central nervous system，and more than half of them are WHO grade IV glioblastomas. Even if surgery，concurrent chemoradiotherapy and adjuvant chemotherapy were applied，median survival of GBM patients is still only 14.2 months. Immunosuppression is an important feature of malignant glioma. Immunotherapy which reverse immunosuppression may be the most promising way to improve the treatment effect of glioma patients in recent years. This article reviews the recent progress of glioma immunotherapy and the research progress of regulatory T cells（Treg）and glucocorticoid-induced tumor necrosis factor receptor（GITR）in the glioma microenvironment. We hope this article will provides new research ideas for glioma immunotherapy.